JP2005535350A - ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用 - Google Patents
ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用 Download PDFInfo
- Publication number
- JP2005535350A JP2005535350A JP2004530093A JP2004530093A JP2005535350A JP 2005535350 A JP2005535350 A JP 2005535350A JP 2004530093 A JP2004530093 A JP 2004530093A JP 2004530093 A JP2004530093 A JP 2004530093A JP 2005535350 A JP2005535350 A JP 2005535350A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- acid sequence
- nucleic acid
- streptococcus uberis
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 166
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 152
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 90
- 241000194054 Streptococcus uberis Species 0.000 title claims abstract description 82
- 229940115922 streptococcus uberis Drugs 0.000 title claims abstract description 82
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 70
- 229960005486 vaccine Drugs 0.000 title claims abstract description 61
- 208000004396 mastitis Diseases 0.000 title description 20
- 239000012634 fragment Substances 0.000 claims abstract description 95
- 230000002163 immunogen Effects 0.000 claims abstract description 57
- 108020004414 DNA Proteins 0.000 claims abstract description 39
- 102000053602 DNA Human genes 0.000 claims abstract description 20
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 3
- 241000283690 Bos taurus Species 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 7
- 241000194017 Streptococcus Species 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 241000588923 Citrobacter Species 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 241000588748 Klebsiella Species 0.000 claims description 4
- 241000194042 Streptococcus dysgalactiae Species 0.000 claims description 4
- 229940115920 streptococcus dysgalactiae Drugs 0.000 claims description 4
- 241000588914 Enterobacter Species 0.000 claims description 3
- 241000223777 Theileria Species 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 241000606646 Anaplasma Species 0.000 claims description 2
- 241000223836 Babesia Species 0.000 claims description 2
- 241000711895 Bovine orthopneumovirus Species 0.000 claims description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 2
- 241001293418 Mannheimia haemolytica Species 0.000 claims description 2
- 241001147662 Neospora caninum Species 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000223104 Trypanosoma Species 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 238000002255 vaccination Methods 0.000 abstract description 14
- 102000039446 nucleic acids Human genes 0.000 abstract description 6
- 108020004707 nucleic acids Proteins 0.000 abstract description 6
- 239000000969 carrier Substances 0.000 abstract description 5
- 108091005461 Nucleic proteins Proteins 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 117
- 210000004027 cell Anatomy 0.000 description 38
- 238000000034 method Methods 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000013598 vector Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 101800000594 Capsid protein 1 Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 108010009719 mutanolysin Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 108091006054 His-tagged proteins Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 150000002411 histidines Chemical class 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 101000743092 Bacillus spizizenii (strain DSM 15029 / JCM 12233 / NBRC 101239 / NRRL B-23049 / TU-B-10) tRNA3(Ser)-specific nuclease WapA Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 101000743093 Bacillus subtilis subsp. natto (strain BEST195) tRNA(Glu)-specific nuclease WapA Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000231230 Suillus bovinus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 101150023479 hsdS gene Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明の22.5kDa蛋白質のアミノ酸配列は21残基の疎水性N末端シグナル配列を含む(配列番号2)。大腸菌で発現させるために、このドメインを欠失させ、当該分野で公知の標準pETベクターに例えば数個のヒスチジンを導入することにより構築したpET由来ベクターpETHis1(アンピシリン耐性)で発現構築物を作製した。図1はT7プロモーターとマルチクローニング部位の5’及び3’末端に数個のヒスチジンを含む該当領域の配列を示す。残基22(下線部コドン)から開始し、付加NdeI制限部位(太字斜体部)をもつフォワードプライマー:
誘導培養液50mlの細菌ペレットを37℃で5分間解凍した。ペレットを溶解用緩衝液(8M尿素,100mM NaCl,50mM NaH2PO4,10mM TrisHCl pH8.0)20mlに再懸濁し、室温で15分間インキュベートした。溶解用混合物のサンプルを後期分析用に保存した。溶解用混合物1.5mlをTalonスピンカラム(Clontech,Palo Alto,California,米国)に加えた。His融合蛋白質を樹脂と5分間結合させた。カラムを2分間700xgで遠心した。溶出液を後期分析用に保存した。融合蛋白質が結合したカラムを溶解用緩衝液1mlで3回洗浄した。洗浄段階の流出液を後期分析用に保存した。6M尿素と100mM EDTAを添加した緩衝液を使用して結合蛋白質を2段階で溶出させた。この方法を使用して22.5kDa蛋白質を大腸菌溶解液から精製することができた(データは示さず)。
大腸菌22.5kDa発現産物の反応性を実証するために、イムノブロットを実施した。
Claims (20)
- 22.5kD ストレプトコッカス・ユベリス(Streptococcus uberis)蛋白質をコードする核酸配列又は前記蛋白質の免疫原フラグメントをコードする前記核酸配列の部分であって、前記核酸配列又は前記その部分が配列番号1に示すストレプトコッカス・ユベリス蛋白質遺伝子の核酸配列に対して少なくとも85%の相同性を有する前記核酸配列又はその部分。
- 配列が配列番号1に示すストレプトコッカス・ユベリス蛋白質遺伝子の核酸配列に対して少なくとも90%、好ましくは93%、より好ましくは95%の相同性を有することを特徴とする請求項1に記載の核酸配列又はその部分。
- 請求項1又は2に記載の核酸配列を含むDNAフラグメント。
- 機能的に連結したプロモーターの制御下に請求項1もしくは2に記載の核酸配列又は請求項3に記載のDNAフラグメントを含む組換えDNA分子。
- 請求項1もしくは2に記載の核酸配列、請求項3に記載のDNAフラグメント又は請求項4に記載の組換えDNA分子を含む生きた組換えキャリヤー。
- 請求項1もしくは2に記載の核酸配列、請求項3に記載のDNAフラグメント、請求項4に記載の組換えDNA分子、又は請求項5に記載の生きた組換えキャリヤーを含む宿主細胞。
- 配列番号2に示すアミノ酸配列に対して少なくとも93%の配列相同性を有することを特徴とする22.5kD ストレプトコッカス・ユベリス蛋白質又は少なくとも33アミノ酸長の前記蛋白質の免疫原フラグメント。
- 配列番号2に示すアミノ酸配列に対して少なくとも94%、好ましくは95%、より好ましくは96%のアミノ酸配列相同性を有する請求項7に記載の22.5kD ストレプトコッカス・ユベリス蛋白質又はその免疫原フラグメント。
- 前記蛋白質又は免疫原フラグメントが請求項1又は2に記載の核酸配列によりコードされることを特徴とする請求項7又は8に記載の22.5kD ストレプトコッカス・ユベリス蛋白質又は前記蛋白質の免疫原フラグメント。
- ワクチンで使用するための請求項7から9のいずれか一項に記載の22.5kD ストレプトコッカス・ユベリス蛋白質又はその免疫原フラグメント。
- ストレプトコッカス・ユベリス感染の治療用ワクチンの製造における、配列番号2に示すアミノ酸配列に対して少なくとも70%、好ましくは80%、より好ましくは85%のアミノ酸配列相同性を有する22.5kD ストレプトコッカス・ユベリス蛋白質又は少なくとも6アミノ酸長の前記蛋白質の免疫原フラグメントの使用。
- ストレプトコッカス・ユベリス感染の治療用ワクチンの製造における、請求項1もしくは2に記載の核酸配列、請求項3に記載のDNAフラグメント、請求項4に記載の組換えDNA分子、請求項5に記載の生きた組換えキャリヤー、請求項6に記載の宿主細胞又は請求項7から9のいずれか一項に記載の蛋白質もしくはその免疫原フラグメントの使用。
- 配列番号2に示すアミノ酸配列に対して少なくとも70%、好ましくは80%、より好ましくは85%のアミノ酸配列相同性を有する22.5kD ストレプトコッカス・ユベリス蛋白質又は少なくとも6アミノ酸長の前記蛋白質の免疫原フラグメントと、薬学的に許容可能なキャリヤーを含むことを特徴とするストレプトコッカス・ユベリス感染の治療用ワクチン。
- 請求項1もしくは2に記載の核酸配列、請求項3に記載のDNAフラグメント、請求項4に記載の組換えDNA分子、請求項5に記載の生きた組換えキャリヤー、請求項6に記載の宿主細胞又は請求項7から9のいずれか一項に記載の蛋白質もしくはその免疫原フラグメントと、薬学的に許容可能なキャリヤーを含むことを特徴とするストレプトコッカス・ユベリス感染の治療用ワクチン。
- 請求項7から9のいずれか一項に記載の蛋白質又はその免疫原フラグメントに対する抗体と、薬学的に許容可能なキャリヤーを含むことを特徴とするストレプトコッカス・ユベリス感染の治療用ワクチン。
- 前記ワクチンがアジュバントを含むことを特徴とする請求項13から15のいずれか一項に記載のワクチン。
- 前記ワクチンがウシに病原性のウイルス又は微生物に由来する付加抗原、前記抗原に対する抗体又は前記抗原をコードする遺伝情報及び/又は医薬成分を含むことを特徴とする請求項13から16のいずれか一項に記載のワクチン。
- 前記ウシに病原性のウイルス又は微生物がウシヘルペスウイルス、ウシウイルス性下痢ウイルス、パラインフルエンザ3型ウイルス、ウシパラミキソウイルス、口蹄病ウイルス、パスツレラ・ヘモリチカ(Pasteurella haemolytica)、ウシ呼吸器合胞体ウイルス、タイレリア(Theileria)種、バベシア(Babesia)種、トリパノソーマ(Trypanosoma)種、アナプラズマ(Anaplasma)種、ネオスポラ・カニナム(Neospora caninum)、黄色ブドウ球菌、ストレプトコッカス・アガラクティエ(Streptococcus agalactiae)、マイコプラズマ、大腸菌、エンテロバクター(Enterobacter)属、クレブシエラ(Klebsiella)属、シトロバクター(Citrobacter)属及びストレプトコッカス・デイスガラクティエ(Streptococcus dysgalactiae)から構成される群から選択されることを特徴とする請求項17に記載のワクチン。
- 請求項1もしくは2に記載の核酸配列、請求項3に記載のDNAフラグメント、請求項4に記載の組換えDNA分子、請求項5に記載の生きた組換えキャリヤー、請求項6に記載の宿主細胞、請求項7から9のいずれか一項に記載の蛋白質又は請求項7から9のいずれか一項に記載の蛋白質に対する抗体と、薬学的に許容可能なキャリヤーを混合することを含む請求項13から18のいずれか一項に記載のワクチンの製造方法。
- 適切な検出手段と、請求項1もしくは2に記載の核酸配列もしくはそのプライマー、又は請求項7から9のいずれか一項に記載の蛋白質もしくはその免疫原フラグメント、又は請求項7から9のいずれか一項に記載の蛋白質に対して反応性の抗体を含む診断キット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02078325 | 2002-08-12 | ||
PCT/EP2003/008704 WO2004018683A1 (en) | 2002-08-12 | 2003-08-06 | Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005535350A true JP2005535350A (ja) | 2005-11-24 |
Family
ID=31896912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004530093A Pending JP2005535350A (ja) | 2002-08-12 | 2003-08-06 | ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7601804B2 (ja) |
EP (1) | EP1532253B1 (ja) |
JP (1) | JP2005535350A (ja) |
AR (1) | AR040830A1 (ja) |
AU (1) | AU2003251694B2 (ja) |
BR (1) | BR0313237A (ja) |
CA (1) | CA2494197C (ja) |
NZ (1) | NZ538075A (ja) |
WO (1) | WO2004018683A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN112409495A (zh) * | 2020-10-28 | 2021-02-26 | 天津农学院 | 一种猪链球菌重组zsd重组亚单位疫苗、重组表位原核质粒、制备和应用 |
PL442091A1 (pl) | 2022-08-25 | 2024-02-26 | Uniwersytet Jagielloński | Sposób i kompozycja diagnostyczna do wykrywania mastitis wywołanego przez E. coli, S. uberis, S. agalactiae lub S. aureus |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
EP0473210B1 (en) | 1990-07-30 | 1994-04-13 | Akzo Nobel N.V. | Recombinant Marek's disease virus |
FR2714074B1 (fr) | 1993-12-20 | 1996-03-01 | Pasteur Institut | Promoteurs des gènes GRA1, GRA2, GRA5 et GRA6 de toxoplasma gondii et vecteurs d'expression comprenant lesdits promoteurs. |
CA2411919C (en) | 2000-06-12 | 2012-07-31 | University Of Saskatchewan | Immunization of dairy cattle with chimeric gapc protein against streptococcus infection |
US6866855B2 (en) * | 2000-06-12 | 2005-03-15 | University Of Saskatchewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
EP1332155B1 (en) | 2000-06-12 | 2006-10-25 | University of Saskatchewan | Immunization of dairy cattle with gapc protein against streptococcus infection |
MX357775B (es) * | 2000-10-27 | 2018-07-20 | J Craig Venter Inst Inc | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
FR2824074A1 (fr) | 2001-04-26 | 2002-10-31 | Pasteur Institut | Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques |
US7005885B1 (en) | 2003-02-21 | 2006-02-28 | Aeluros, Inc. | Methods and apparatus for injecting an external clock into a circuit |
US8043109B2 (en) | 2009-07-27 | 2011-10-25 | Avx Corporation | Wire to board connector |
-
2003
- 2003-08-06 BR BR0313237-4A patent/BR0313237A/pt not_active IP Right Cessation
- 2003-08-06 CA CA2494197A patent/CA2494197C/en not_active Expired - Fee Related
- 2003-08-06 AU AU2003251694A patent/AU2003251694B2/en not_active Ceased
- 2003-08-06 US US10/524,198 patent/US7601804B2/en not_active Expired - Fee Related
- 2003-08-06 NZ NZ538075A patent/NZ538075A/en not_active IP Right Cessation
- 2003-08-06 WO PCT/EP2003/008704 patent/WO2004018683A1/en active Application Filing
- 2003-08-06 JP JP2004530093A patent/JP2005535350A/ja active Pending
- 2003-08-06 EP EP03792264.8A patent/EP1532253B1/en not_active Expired - Lifetime
- 2003-08-08 AR AR20030102870A patent/AR040830A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR0313237A (pt) | 2005-07-12 |
AU2003251694B2 (en) | 2009-09-17 |
AR040830A1 (es) | 2005-04-20 |
AU2003251694A1 (en) | 2004-03-11 |
CA2494197A1 (en) | 2004-03-04 |
WO2004018683A1 (en) | 2004-03-04 |
EP1532253B1 (en) | 2014-04-30 |
CA2494197C (en) | 2012-10-09 |
EP1532253A1 (en) | 2005-05-25 |
NZ538075A (en) | 2006-05-26 |
US20050255125A1 (en) | 2005-11-17 |
US7601804B2 (en) | 2009-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090053228A1 (en) | Lawsonia intracellularis subunit vaccines | |
US20090017048A1 (en) | Novel Brachyspira hyodysenteriae vaccine | |
ES2335668T3 (es) | Vacuna de sub-unidad de lawsonia intracellularis. | |
JP2005514041A (ja) | ミコバクテリウム・パラツベルクローシス感染の診断薬及びワクチン | |
US7279167B2 (en) | Infectious Salmon Anaemia virus vaccine | |
US20070212373A1 (en) | Lawsonia Intracellularis 26 Kd Subunit Vaccine | |
EP1532253B1 (en) | Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine | |
US7514547B2 (en) | Helicobacter felis vaccine | |
CA2548750A1 (en) | Lawsonia intracellularis 26 kd subunit vaccine | |
CA2281913A1 (en) | A vaccine against piscirickettsia salmonis based on a recombinant 17 kd protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060327 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090629 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090915 |